Technologies

AIDD is an integrated tool and a radically new way to discovery new drugs for neurodegenerative diseases (Alzheimer’s, Epilepsy, Ageing, etc.).

The proposed technology is based on the micro-fabrication of electrodes in order to generate surface acoustic waves (SAW) with well-defined frequencies, on piezoelectric substrates. The operating principle of a surface acoustic wave sensor is linked to the variation of the characteristics of the acoustic wave that propagates on the device (e.g. wave velocity on the substrate, etc.) caused by the interaction with the environment (e.g. interaction of an analyte on the surface of the device, deformation of the substrate, etc.).

Silicon nanowires (SiNWs) are 1D structures with diameter ranging from few tens to hundreds of nanometers and length varying from few tens of nanometers to millimiters. SiNWs are fabricated in the labs of the IMM-CNR, Rome Unit,  by using bottom-up technologies such as plasma enhanced chemical vapor deposition (PECVD) at low growth temperature ((≤350°C), allowing the use of plastic and glassy substrates. Their electrical properties can be tuned by controlling the p/n doping during the growth.

The aim of the research group is the creation of 3D models (microorgan/ organoids) constructed using samples obtained from patients, both biopsy samples and samples collected with non-invasive techniques (exhaled breath condensate, induced sputum, blood samples).

This technology is based on an algorithm able to provide the probability of being asthmatic with high accuracy. This probability is based on the evaluation of respiratory function and, specifically, of forced expiratory vital capacity in the first second (FEV₁), in resting conditions, and 20 minutes after administration of a bronchodilator drug.

We present a technology for the multiscale isolation (analytical-laboratory-production) of Extracellular Vesicles (VE), which overcomes the limitations of the currently available methods. As opposed to traditional "affinity-based" systems that exploit antibodies, our technology represents a radical paradigm shift in the development of affinity probes for vesicles, i.e.